

Form PTO-1449 (modified)		Atty. Docket No.: <b>ARCD:389US</b>	Serial No.: <b>10/751,606</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: <b>Mark J. RATAIN <i>et al.</i></b>	
		Filing Date: <b>January 5, 2004</b>	Group: <b>1634</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C222	"Prosecution history for 90/007,601," Reexamination of United States Patent Number 6,395,481
	C223	Cote <i>et al.</i> , "UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan," <i>Clin. Cancer Res.</i> , 13(11):3269-3275, 2007.
	C224	Falandry <i>et al.</i> , "Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial," <i>J. Clin. Oncology</i> , 2007 ASCO Annual Meeting Proceedings Part I, 25(18S):2510, 2007.
	C225	Innocenti <i>et al.</i> , "A genotype-directed phase I study of irinotecan in advanced cancer patients," <i>J. Clin. Oncology</i> , 2007 ASCO Annual Meeting Proceedings Part I, 25(18S):2502, 2007.
	C226	Iyer <i>et al.</i> , "Glucuronidation of TAS-103: A Novel Anticancer Agent," <i>Proc. Am. Soc. Clin. Oncol.</i> , 17:187a, No. 722, 1998.
	C227	Owens and Ritter, "The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes," <i>Pharmacogenetics</i> , 2:93-108, 1992.
	C228	Takahashi <i>et al.</i> , "The Role of Glucuronidation in 7-Ethyl-10-hydroxycamptothecin Resistance in vitro," <i>Jpn. J. Cancer Res.</i> , 88:1211-1217, 1997.
	C229	Utsugi <i>et al.</i> , "Antitumor Activity of a Novel Quinoline Derivative, TAS-103, with Inhibitory Effects on Topoisomerases I and II," <i>Jpn. J. Cancer Res.</i> , 88:992-1002, 1997.

25797494.1

EXAMINER: /Sarae Bausch/

DATE CONSIDERED: 08/12/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.